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Abstract. Myosin couples ATP hydrolysis to the trans- 
location of actin filaments to power many forms of cel- 
lular motility. A  striking feature of the structure of the 
muscle myosin head domain is a 9-nm long "lever arm" 
that has been postulated to produce a 5-10-nm power 
stroke. This motion must be coupled to conformational 
changes around the actin and nucleotide binding sites. 
The linkage of these sites to the lever arm has been an- 
alyzed by site-directed mutagenesis of a conserved gly- 
cine residue (G699) found in a bend joining two helices 
containing the highly reactive and mobile cysteine resi- 
dues, SH1 and SH2. Alanine mutagenesis of this gly- 
cine (G699A) dramatically alters the motor activity of 
skeletal muscle myosin, inhibiting the velocity of actin 
filament movement by >100-fold. Analysis of the de- 
fect in the G699A mutant myosin is consistent with a 
marked slowing of the transition within the motor do- 
main from a strong binding to a weak binding interac- 
tion with actin. This result is interpreted in terms of the 
role of this residue (G699) as a pivot point for motion 
of the lever arm. The recombinant myosin used in these 
experiments has been produced in a unique expression 
system. A  shuttle vector containing a regulated muscle- 
specific promoter has been developed for the stable ex- 
pression of recombinant myosin in C2C12 cells. The 
vector uses the promoter/enhancer region, the first two 
and the last five exons of an embryonic rat myosin 
gene, to regulate the expression of an embryonic 
chicken muscle myosin cDNA. Stable cell lines trans- 
fected with this vector express the unique genetically 
engineered myosin after differentiation into myotubes. 
The myosin assembles into myofibrils, copurifies with 
the endogenous myosin, and contains a complement of 
muscle-specific myosin light chains. The functional ac- 
tivity of the recombinant myosin is readily analyzed 
with an in vitro motility assay using a species-specific 
anti-S2 mAb to selectively assay the recombinant pro- 
tein. This expression system has facilitated manipula- 
tion and analysis of the skeletal muscle myosin motor 
domain and is also amenable to a wide range of struc- 
ture-function experiments addressing questions unique 
to the muscle-specific cytoarchitecture and myosin iso- 
forms. 
M 
YOSIN is the crucial motor component of muscle 
contraction and essential to numerous forms of 
cellular movements (Warrick and Spudich, 1987; 
Cheney et al.,  1993).  The muscle-specific isoform of this 
motor molecule assembles into bipolar thick filaments that 
interdigitate with thin actin filaments in a highly ordered 
cytoskeletal structure called the myofibril (Lowey, 1994). 
There is  now a  large  family of actin-based  motors  that 
have been identified based on sequence and functional ho- 
mology with the motor domain of skeletal muscle myosin 
(Hammer,  1991).  They share  a  common minimal  motor 
domain with >50% sequence homology with muscle myo- 
sin.  Those myosins that have been isolated and  assayed 
have an actin-activated ATPase that couples ATP hydrol- 
ysis to the translocation of actin filaments. 
The structure of the  head  domain of chicken skeletal 
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muscle myosin reveals an asymmetric molecule with sec- 
ondary structure dominated by many long c~-helices (Rayg 
ment et al., 1993b). One exceptionally long helix spans 85 A 
and  is  stabilized  by  interactions  with  the  myosin  light 
chains. Based on several lines of evidence, it has been pro- 
posed that this light chain binding domain acts as a semi- 
rigid "lever arm" to amplify and transmit conformational 
changes in  the  nucleotide and  actin  binding sites  of the 
myosin head (Lowey et al.,  1993b;  Rayment et al.,  1993a; 
Jontes et al., 1995; Whittaker et al., 1995). The nucleotide 
and actin binding sites are formed by ~780 residues from 
the amino terminus of the myosin heavy chain. This frag- 
ment represents the minimal motor domain and can sup- 
port limited sliding movement of actin filaments (Itakura 
et al., 1993; Waller et al., 1995). 
A  significant feature of the myosin structure is a deep 
cleft ~4 nm long that splits the actin binding site between 
two  subdomains  and  terminates  beneath  the  nucleotide 
binding pocket (Rayment et al.,  1993a,  b). Closure of the 
cleft on binding to actin and its modulation by nucleotide 
have been proposed as a mechanism for coupling actin ac- 
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force production (Rayment et al., 1993a; Spudich, 1995). It 
has been postulated that these changes are linked to the 
movement of the  long lever arm to  produce  a  5-10-nm 
power stroke  (Rayment et  al.,  1993a;  Finer  et  al.,  1994; 
Spudich, 1995). 
Support for this hypothesis comes from experiments de- 
signed to alter the mechanical properties of the lever arm. 
Weakening the lever arm by removal of one or both light 
chains results in a reduction in actin filament velocity and 
force production  (Lowey et al.,  1993b;  VanBuren  et  al., 
1994).  Truncation of the lever arm by removal of one light 
chain binding site also produces a reduction in filament ve- 
locity (Uyeda and Spudich, 1993), and addition of an extra 
binding site, lengthening the lever arm, increases the ve- 
locity (Uyeda et al., 1996).  The truncated motor domains 
completely lacking  the  light  chain  binding  helix  show  a 
large  decrease  in  filament  velocity with  little  effect on 
ATPase activity (Itakura et al., 1993; Waller et al., 1995). 
Structural evidence for the lever arm hypothesis has come 
from helical  reconstruction  of actin  filaments decorated 
with myosin heads  (Jontes et al.,  1995;  Whittaker  et al., 
1995). When ADP is bound to the acto--myosin complex, 
the light chain binding domain moves like a rigid lever by 
32  °  . Modeling the movement places the "pivot point" of 
the lever in the vicinity of several important structural ele- 
ments in the motor domain, including two helices contain- 
ing the reactive sulfhydryls. 
The goal of this work is to localize the pivot point where 
the lever arm emerges from the motor domain. Our atten- 
tion was directed to the two short helices carrying the re- 
active sulfhydryls, SH1 and SH2 (C707 and C697), because 
they are located in a highly conserved segment of the mo- 
tor  domain,  which  appears to be highly  mobile as  well. 
These two sulfhydryls can be cross-linked by a  variety of 
reagents bridging distances of 4-18 _A (Wells et al., 1980). 
Cross-linking SH1 and SH2 can trap nucleotide in the ac- 
tive site (Wells and Yount,  1979).  Chemical modification 
of SH1 or SH2 dramatically alters myosin ATPase activity 
and  actin  binding  affinity, and  nucleotide  binding  alters 
the separation between SH1 and SH2 (Reisler et al., 1974; 
Pemrick and Weber, 1976; Dalbey et al., 1983). These re- 
sults suggested that SH1 and SH2 would reside on a flexible 
loop. However, these residues are located on well-defined 
a-helix segments. The helices in the myosin structure are 
joined by a turn, and the sulfhydryls are separated by 18 
(Rayment et al., 1993b). A conserved glycine residue (G699) 
that is found in all myosin sequences is located in the turn 
that links the two reactive sulfhydryl helices, and we rea- 
soned  that  this  residue  might be key to  the  mobility of 
these sulfhydryls. Furthermore, the SHl-containing helix 
is linked  to the  lever arm, so motion within  this  region 
could be directly coupled to force transmission. 
We have tested this idea by using alanine mutagenesis to 
perturb the motion around this highly conserved glycine 
(G699). To accomplish this, we have developed a unique 
approach for the preparation of fast skeletal muscle myo- 
sin that is based on regulated expression of a recombinant 
myosin gene in a mouse myogenic cell line that differenti- 
ates and forms contractile myotubes. This expression sys- 
tem was combined with  a  simple technique  for selective 
isolation of the recombinant protein to assay the motor ac- 
tivity in vitro. These data demonstrate the importance of 
motion in the reactive sulfhydryl region and identify G699 
as a likely pivot point. 
Materials and Methods 
Expression Vector Construction 
Skeletal muscle myosin expression vectors were constructed from a full- 
length chicken embryonic fast skeletal muscle myosin heavy chain eDNA 
that was isolated from a 14-d in ovo pectoralis major eDNA library (Mo- 
linaet al., 1987). A chimeric chicken myosin cDNA was created by replac- 
ing the 5'-segment of the embryonic myosin cDNA with the correspond- 
ing segment from an adult pectoralis muscle myosin gene (Robbins et al., 
1986). This was done to incorporate the adult segment that encodes amino 
acid  residues 1~0  of the myosin protein  sequence and contains three 
unique epitopes recognized by mAbs (Winkelmann et al., 1993). A plasmid 
containing a  rat embryonic myosin heavy chain minigene (pE2600) was 
kindly provided by Dr. Vijak Mahdavi (Harvard Medical School, Boston, 
MA). This plasmid contains the complete embryonic rat skeletal muscle 
myosin promoter/enhancer region (1.4 kbp), the first two exons, a  large 
deletion fusing the third exon to the 37th exon, and the last four exons 
(38-41) of the rat myosin gene (Bouvagnet et al., 1987). The selection vec- 
tor, pSV2Neo, was a gift from Dr. Jean Schwarzbauer (Princeton Univer- 
sity, Princeton, N J). This plasmid contains a neomycin phosphotransferase 
gene linked to the SV-40 early promoter region and SV-40 late sequences 
that contain splicing and polyadenylation signals (Southern and Berg, 1982). 
To construct the Y-end of the expression vector, a  1.67-kbp HindlII- 
BamHI fragment containing the complete promoter/enhancer region of 
the rat myosin gene and a 0.56-kbp BamHI-Cfrl0I fragment containing 
exons 1-2 were isolated from pE2600.  Synthetic oligonucleotides corre- 
sponding to a 22 mer (CAT GGT GTI  r GGC CTG AGT CAC A) and a 
26 mer (CCG GTG TGA CTC AGG CCA ACA CCA TG) were synthe- 
sized (Operon Technologies, Inc., Alameda, CA), annealed, and phosphor- 
ylated to obtain a Cfrl0I-NcoI blunt end linker for introducing a transla- 
tion start site and unique NcoI cloning site at the 3'-end of the second 
exon of the rat  myosin gene. The  1.67-kbp HindllI-BamHl  fragment, 
0.56-kbp  BamH/-Cfrl0I  fragment, and  Cfrl01-NcoI  blunt  linker  were 
cloned into the HindlII-SmaI sites of pGEM3 (Promega Corp., Madison, 
WI). The resulting intermediate plasmid contains the complete promoter 
and first two exons of the embryonic rat myosin gene with a unique Ncol 
restriction site for the insertion of chicken myosin cDNAs. 
The 3'-end of the rat myosin gene corresponding to exons 37-41 is con- 
tained in  a  1.93-kbp Pstl-EcoRI  fragment of pE2600.  The  Pstl  site  is 
shared between rat and embryonic chicken myosin cDNAs. A 365-bp Ncol- 
PstI fragment from the embryonic chicken myosin cDNA corresponding 
to  exon 37 of the rat myosin gene was ligated  together with  the PstI- 
EcoRI fragment into the Ncol-EcoRI sites of the intermediate plasmid. 
Together, the 5'- and 3'-ends of the rat myosin gene complete the shuttle 
vector pGrM. The construction was confirmed by restriction mapping and 
sequencing across all junctions. The  embryonic chicken  myosin heavy 
chain cDNA was cloned between the NcoI site and a unique Xhol site in 
the pGrM vector. The resulting vector was designated pGrMHC. 
Site-directed Mutagenesis 
PCR was used to introduce base changes within the myosin cDNA. The 
primer, TCC GGA TCC CTT CCA GCA CGG CGT TAC, overlaps the 
codon for G699 and was designed to insert two single base changes: one 
change converted the glycine codon to an alanine codon, and the other 
change,  18  bases away,  is  a  silent mutation  that  introduces  a  unique 
BamHI restriction site. This antisense strand primer was paired with an 
upstream primer overlapping a unique BglIl restriction site to produce a 
740-bp PCR product. A  second sense strand primer, GGA AGG GAT 
CCG GAT "ITG C, also containing the silent mutation for the unique 
BamHI site, was paired with a unique downstream primer overlapping a 
ClaI cloning site to produce a 320-bp PCR product. The two PCR prod- 
ucts were  completely sequenced; then the mutagenized region was  in- 
serted into the pGrMHC plasmid to yield pGrMHC/G699A. 
Cell Culture and Transfections 
The myogenic cell line, C2C12 (ATCC CRL 1772), was purchased from 
American Type Culture Collection (Rockville, MD). This is a mouse myo- 
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muscle after injury (Yaffe and Saxel,  1977). For routine passage, C2C12 
myoblasts were plated at 2  ×  103 cells  per cm  2 and maintained in 10% 
FBS,  90%  DME (GIBCO BRL, Gaithersburg, MD) at 37°C in 5% CO2 
(Moncman et al., 1993). The cells were passed every 2-3 d when 60-70% 
confluent. For formation of C2 myotubes, the cells were transferred to dif- 
ferentiation  media  (10%  horse serum,  1%  FBS,  89%  DME)  as  they 
reached confluence. The cells  line  up and fuse into multinucleated myo- 
tubes. 
Primary cultures of chicken embryonic breast muscle were prepared by 
dissection of dll  embryos and enzymatic dissociation of the tissue. The 
cultures were maintained in 10%  FBS, 90%  DME/FI2 medium (Sigma 
Chemical Co., St. Louis, MO). The breast muscle from two embryos was 
removed, rinsed in PBS,  minced with a scalpel  in 2 ml of PBS,  and vor- 
texed for 30 s. 2 ml of 0.25% trypsin in PBS was added to the tissue and in- 
cubated at 24°C for 10-20 rain. The tissue was collected  by centrifugation 
in a clinical centrifuge for 5 min at 1,000 rpm and washed with 10% FBS, 
90%  DME/F12. The cells were then dispersed by treatment with 2,000 U 
of collagenase in 10 ml of DME for 2 h at 37°C with gentle pipetting every 
half hour. Large tissue clumps were removed by filtering the cells through 
a nylon membrane. The cells were collected,  washed with 10% FSB, 90% 
DME/FI2, and plated at 6 ×  10  -~ cells per cm  ~. The media were changed 
every other day,  and the cells  differentiated as they approached conflu- 
ence. 
Stable  transfection of C2C12  cells  was performed using a  liposome- 
mediated  procedure  with  Lipofectin  (GIBCO  BRL)  according  to  the 
manufacturer's recommendations, but optimized for use with the C2C12 
cell  line  as previously described  (Moncman et  al.,  1993). C2  myoblasts 
were plated at 6 ×  I(P cells per cm  2 in 6-well cluster plates and grown at 
37°C for 24 h (cells  were 50-60%  confluent at the time of transfection). 
For transfections, 5/.tg of DNA and 35 &g of Lipofectin were mixed and 
added. After incubation at 37°C for 5 h, the transfection was stopped by 
dilution with 3 ml of 20% FBS in DME. For most transfections the molar 
ratio of myosin gene to selection vector (pSV2Neo) was 50:1. 
The transfected cells were split into medium containing 1 mg/ml G418 
(Geneticin; Life  Technologies, Inc.,  Gaithersburg, MD) and plated in a 
100-mm culture dish 36-48 h after transfection. The selection media was 
changed every 3 d to remove debris. Isolated colonies were visible 7-10 d 
after transfection. Colonies were picked  using a  filter lift  trypsinization 
method (Domann and Martinez,  1995). The filters  were transferred to a 
24-well  cluster plate and expanded to larger plates as they reached 50- 
60%  confluence. Isolated clonal lines were induced to fuse, and the myo- 
tubes were assayed for myosin expression by Western blot assay.  Lines 
that tested positive for expression of the myosin gene were expanded, fro- 
zen at -80°C, and stored in liquid nitrogen. 
PCR Amplification 
Genomic DNA was prepared from 80-100% confluent 100-ram plates of 
C2 cell lines using standard procedures (Sambrook et al., 1990). Amplifi- 
cation of the genomic DNA (100 ng) with the PCR was for 30 cycles  of 
94°C for 30 s, 58°C for 30 s, and 72°C for 30 s with 1-~M  primers, CTG 
GAC ATC GCT GGC TTT G  and TTC TCT TGC AGC AGG GAC 
ACC, using Taq polymerase (Boehringer Mannheim GmBH, Mannheim, 
Germany). The primers were selected  to flank the region encoding the 
G699A point mutation and to produce a 1.28-kbp amplified product. To- 
tal  RNA was isolated using TRIzol Reagent (Life Technologies, Inc.) ac- 
cording to the manufacturer's recommendations. The cDNA was synthe- 
sized from 500  ng of total RNA primed with random hexamers using 
M-MLV  reverse transcriptase (RT) ~ (Life  Technologies, Inc.). Primers 
used for PCR amplification were designed to overlap splice junctions on 
the 5'- and the Y-end of the processed myosin mRNA. The primers for 
RT-PCR of the 5'-end of the mRNA were: CTG CCA CAG TCA GAG 
GTC CC (position 10-29) and GCT CCA GGC TGT TGA AAT C (posi- 
tion 1526-1508).  The primers' 3'-end of the RNA were: GCT GAG CCA 
TGC  CAA  CCG  CCA  G  (position 4993-5014)  and  GCA TGT GGA 
AAG GGG TTA CGT GG (position 6027-6005).  Amplification of the 
cDNA (100 ng) with 1-p.M primers using Taq polymerase was for 30 cy- 
cles consisting of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s. PCR prod- 
ucts  were analyzed  by Tris-acetate  EDTA  agarose gel  electrophoresis 
(Sambrook et al., 1990). 
1. Abbreviations used in this paper: F-actin,  filamentous actin; RT, reverse 
transcriptase. 
Monoclonal Antibodies 
A library of mAbs that react with skeletal muscle myosin heavy chain was 
prepared and characterized as previously described (Winkelmann et al., 
1983, 1993, 1995; Winkelmann and Lowey, 1986). The IgG class  mAbs 
were purified on protein A-Sepharose from ascites fluid obtained by pas- 
sage of hybridoma lines through CAF1/J mice (Winkelmann et al., 1983). 
All of the antibodies used in this study were extensively characterized for 
their patterns of cross-reactivity with myosin from different developmen- 
tal  stages  and  species  (Moncman,  1993). mAbs were conjugated  with 
FITC, rhodamine isothiocyanate, or biotin as previously described (Monc- 
man et al., 1993). For immunofluorescence microscopy, cells were grown 
on glass coverslips that were coated with 0.1~9.5% porcine gelatin (Sigma 
Chemical  Co.) and processed as previously described (Moncman et al., 
1993). 
Isolation of Myosin  from (?2 Myotubes 
Confluent C2 myoblasts were switched to fusion media, and the differenti- 
ated myotubes were processed 6-10 d later. The cell layer was rinsed twice 
with 5-10 ml cold PBS. Then l  ml of Triton extraction buffer (TEB: 0.5% 
Triton X-100, 150 mM NaCl, 10 mM Imidazole, pH 7.0, 0.2 mM PMSF, 1.0 
mM D'IT) was added per 100-mm plate, and the cell  layer was scraped 
and transferred to a Dounce homogenizer (Kontes Glass Co., Vineland, 
NJ). Each plate was rinsed with an additional 1 ml of TEB, and the rinse 
was transferred to the next plate. The cell suspension was homogenized 
10-15 strokes on ice, and then pelleted for 10 rain at 10,000 g at 4°C. The 
cell pellet was washed twice with TEB and repelleted. The Triton-insolu- 
ble fraction was extracted with a small volume (~0.5 ml per plates) of high 
salt buffer (HSB: 0.5 M KCI, 5 mM MgCl2, 5 mM Tris-HCI, pH 8.0, 1 mM 
DTT, 0.2 mM PMSF) with 5 mM neutralized ATP added. The pellet was 
resuspended by gentle homogenization, and then incubated on ice for 15 
min with occasional gentle mixing. The cell debris was pelleted at 10,000 g 
for 10 min at 4°C. The high salt soluble extract was dialyzed  against 1/10 
diluted high salt buffer without ATP at 4°C overnight (>16 h). The acto-- 
myosin pellet was collected  by centrifugation at 10,000 g for 10 min at 4°C 
and resuspended in a minimal volume of HSB (25 mM Imidazole, pH 7.6, 
0.3 M KCI, 4 mM MgCI2) supplemented with 1 mM ATP. The filamentous 
actin  (F-actin) was pelleted  at  90,000 rpm for 21  min in a  rotor (TLA 
100.2; Beckman Instruments, Inc., Palo Alto, CA) at 4°C, and the myosin- 
containing  supernatant  was  recovered.  Further  purification  by  ion- 
exchange chromatography on a Mono Q HR5/5 column (Pharmacia Fine 
Chemicals,  Piscataway,  N J) was done after dialysis into 40 mM sodium py- 
rophosphate, pH 7.5,  I mM DTT. The myosin was eluted with a linear 
0M).5 M NaCI gradient in the pyrophosphate buffer. 
Antibody Capture and Motility Assays 
Preparation of the antibody capture surfaces for motility assays has been 
described in detail  (Winkelmann et al., 1995). Briefly,  mAb 10F12.3 was 
bound to nitrocellulose-coated  glass coverslips by incubation with 150 i~g/ml 
mAb in PBS  or Imidazole-buffered saline  for 15 min at 24°C. The anti- 
body-coated surface was blocked with 1% BSA for 15 rain, transferred to 
myosin diluted  in HSB supplemented with 1%  BSA (HSB/BSA), and 
incubated  2-4  h  in  a  humidified chamber at  4°C. The  coverslips were 
washed twice by transferring to 150 ~LI of HSB/BSA for 5 min per wash, and 
then rinsed twice by transferring to a 150-~1 drop of motility buffer (25 mM 
Imidazole, 25 mM KCI, 4 mM MgCI2, 0.2 mM CaCI2, 5 mM 2-mercapto- 
ethanol, 1 mM ATP, pH 7.6) for 30-60 s. The excess motility buffer was 
wicked  off,  and  the coverslip mounted on 20  ~1 of 1-3 nM phalloidin- 
labeled F-actin  on a small parafilm ring affixed  to an alumina slide  with 
vacuum grease. 
Phalloidin-rhodamine-labeled  actin  was diluted  with  motility  buffer 
supplemented with 0.5%  2-mercaptoethanol, 0.1  mg/ml glucose oxidase, 
0.018  mg/ml catalase,  and  2.3  mg/ml glucose to reduce  photooxidation 
(Kishino and Yanagida, 1988). In all assays the MgATP concentration was 
increased to 7.5 mM, and 0.5% methyl cellulose  (1,500 centipoises per 2% 
aqueous solution; Sigma Chemical Co.) was included.  This chamber was 
observed with a  ×100 plan apochromat (1.3 NA) objective  on a micro- 
scope (BH-2; Olympus Corp. of America, New Hyde Park, NY) equipped 
with epifluorescence optics illuminated with a 100 W mercury light source 
and rhodamine filter set. Images were projected with a x3.3 TV tube onto 
the photocathode of a microchannel plate image intensifier (Hamamatsu 
Photonics, Bridgewater, N  J) optically  coupled to a video camera and re- 
corded with an S-VHS video recorder. The temperature of the alumina 
slide  was maintained at 27°C with a Peltier stage heating/cooling device 
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sealed chamber can be observed for >2 h; however, measurements were 
taken within 30 min of slide preparation. 
Motion Analysis 
Videotaped motility assay data are analyzed with a semi-automated fila- 
ment tracking program (Bourdieu et al.,  1995).  Individual video frames 
are acquired from a frame accurate VCR (Sanyo GVR-S950; Sanyo Fisher 
Corp., Compton, CA) and digitized on a workstation (Silicon Graphics, 
Inc., Mountain View, CA). Each digitized frame is processed by adjusting 
the intensity and contrast with parabolic corrections, and then applying 
user-defined threshold and rank-depression filters to separate individual 
filaments from background and refocus the filaments before binarization. 
The boundary and coordinates for every filament in each frame are com- 
pressed and stored to produce a database containing frame number, posi- 
tion, and shape of the filaments. Video segments from 2--8 min are pro- 
cessed in this manner to produce a data set for a single assay condition. 
For fast-moving filaments, every frame is analyzed; for very slowly moving 
filaments, a  time-lapse feature is used to  vary the sampling from 3-30 
frames per s. 
The database of defined filaments is analyzed with a separate applica- 
tion to define the connectivity in time of the individual filaments and to 
assign a label to each filament that can be propagated in time. Limitations 
in  assignment of unique  labels  have  been  discussed (Bourdieu  et  al., 
1995).  Literally  hundreds  of filaments can  be  uniquely  identified and 
tracked with this software. The tracks of individual filaments are derived 
from the skeletonization of the overlapping filament shapes in successive 
frames. The directed motion of the filaments is defined by mapping the 
mean arc-length coordinate of the filament onto the track to produce a 
time-displacement plot. These plots are analyzed to define the filament 
velocity. This analysis automatically extracts the movements of many fila- 
ments without selection bias. However, stationary filaments and trajecto- 
ries of <20 frames are routinely discarded, so the resulting probability dis- 
tributions  lack  a  zero  velocity component.  The  database  of digitized 
filaments can be analyzed in a variety of ways, including the creation of 
time-lapse averages of any number of successive video frames. This is 
used to represent the quality of movement over a defined period of time. 
A TPases, Myosin Quantitation, Electrophoresis, and 
Western Analysis 
Actin-activated myosin ATPase activity was measured in motility buffer 
at 30°C with 10 ~M F-actin by measuring phosphate release using the Mal- 
achite green assay (Kodama et al.,  1986). Myosin samples were immobi- 
lized on  12-mm-diam glass coverslips via the antibody capture method, 
and  then floated on 450-~1 drops of assay buffer. Aliquots were with- 
drawn at intervals, and phosphate content was measured. At the comple- 
tion of the assay, the coverslip surfaces were washed to remove excess 
F-actin, and then the bound myosin was eluted with hot 1% SDS sample 
buffer and analyzed by gel electrophoresis according to Laemmli (1970). 
Densitometry of the myosin heavy chain region of the stained gel was 
used to normalize the ATPase activity data. To measure the concentration 
of recombinant myosin in different preparations, serial dilutions of myosin 
samples were dot blotted, followed by immunodetection with a recombi- 
nant myosin specific mAb (4H7.6) and densitometry. Adult chicken pec- 
toralis myosin contains the identical epitope and was used as the standard 
in this assay. Electrophoretic transfer of cell extracts to nitrocellulose (BA 
83; Schleicher & Schuell, Keene, NH) was done at 6 V/cm for 1 h. Anti- 
body binding to nitrocellulose replicas (Western and dot blots) was de- 
tected with HRP-conjugated goat anti-mouse IgG  (GIBCO  BRL)  fol- 
lowed by Laminol chemiluminescence  (Pierce Chemical Co., Rockford, IL). 
Results 
Development of a Muscle Myosin Expression System 
We wanted to develop a system capable of producing skel- 
etal muscle myosin for biochemical assays, but also able to 
assemble muscle-specific filaments. A variety of myogenic 
cell lines are available that are readily transfected with ex- 
ogenous genes and are capable of differentiating into myo- 
tubes that spontaneously contract. An excellent example is 
the  mouse myogenic cell line,  C2C12  (Yaffe and  Saxel, 
1977).  This cell line has been used extensively to define 
muscle-specific promoter elements necessary for tempo- 
rally  regulated  and  tissue-specific  expression  of muscle 
genes. For example, the embryonic rat skeletal muscle myo- 
sin promoter is active in C2C12 cells and has been exten- 
sively characterized in transient transfection assays using re- 
porter gene constructg (Bouvagnet et al., 1987; Moncman, 
1993). This promoter was selected to drive the expression 
of a chicken myosin heavy chain cDNA in C2C12 cells. 
We  constructed  a  plasmid,  pGrMHC,  containing  the 
complete rat embryonic skeletal muscle myosin promoter/ 
enhancer region (1.4 kbp) and the first two noncoding ex- 
ons of the rat gene, and a chicken myosin cDNA fused in- 
frame to the 37th exon of the rat gene and including the 
last four exons (38--41) of the rat myosin gene (Fig. 1 A). 
In this expression plasmid, the recombinant myosin gene is 
under the control of a rat myosin promoter and contains 
splicing signals for processing of the primary transcript to 
produce a myosin mRNA with native 5'  and 3'  untrans- 
lated regions. The vector was designed to contain unique 
restriction sites for easy insertion and substitution of seg- 
ments of the chicken myosin cDNA. 
The protein encoded by the recombinant myosin gene is 
also quite unique (Fig. 1 B). The NH2 terminus contains 
the first 60 residues of adult chicken pectoralis muscle myo- 
sin,  which contains three unique epitopes and was  engi- 
neered into the gene for easy immunodetection (Winkel- 
mann  et  al.,  1993).  The  next  1760  amino  acids  of  the 
protein are encoded by the embryonic chicken fast muscle 
myosin eDNA, and the last 123 amino acids are encoded 
by exons 37--41 of the embryonic rat myosin gene. Thus, 
the recombinant gene product is a three-part chime~'a. The 
junctions between the different segments  of the  protein 
were engineered into conserved regions of the related pro- 
Figure 1.  Block diagram of the myosin gene coding region of the 
shuttle vector that was developed for the stable expression of re- 
combinant myosin in C2C12 cells. (A) The chimeric myosin gene 
was constructed from segments of an embryonic rat muscle myo- 
sin gene (Strehler et  al., 1986; Bouvagnet et  al., 1987)  and con- 
tains the promoter/enhancer region, the first two exons, and the 
last  five  exons  of the  rat  gene.  The  chicken  myosin  cDNA  is 
cloned between the NcoI  and XhoI sites shown. The  insert de- 
picted here was cloned into the HindlII  and EcoRI sites of the 
vector pGEM3  (Promega  Corp.).  (B)  The  myosin heavy  chain 
encoded by  the  vector  contains  the  first 60  amino  acids  of an 
adult  fast chicken myosin gene, including three epitopes recog- 
nized by species specific mAbs. The bulk of the protein (residues 
61-1,822) is encoded by an embryonic chicken fast myosin cDNA. 
The last 123 residues are contributed by the last five exons of the 
embryonic rat myosin gene, as is the 3'-untranslated region of the 
myosin mRNA. The vector has been engineered to facilitate ma- 
nipulation of embryonic chicken muscle myosin cDNAs. 
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domains. 
Recombinant  myosin  genes  were  introduced  into  the 
C2C12 myogenic cell line by cotransfection with a  selec- 
tion vector containing a drug resistance marker (pSV2 Neo) 
using  a  liposome-mediated transfection protocol (Monc- 
man et al.,  1993).  One gene encoded the recombinant chi- 
meric myosin and, for simplicity, is referred to as "wild- 
type" myosin gene. The other gene containing a glycine to 
alanine mutation at residue 699 (G699A) of the myosin S1 
structure is referred to as "G699A mutant" myosin gene. 
Individual  drug-resistant  colonies  were  screened for ex- 
pression of the recombinant myosin. The rat myosin pro- 
moter is  only active when the myoblasts withdraw from 
the cell cycle, align, and fuse during differentiation. Trans- 
fected C2C12 colonies were induced to differentiate, and 
after 6 d, most of the clones had formed multinucleated 
myotubes.  A  crude  cytosketeton fraction was  prepared 
from  the  undifferentiated  myoblasts  and  6-d-old  myo- 
tubes, and this fraction was screened for the recombinant 
myosin by SDS-PAGE and Western blotting (Fig. 2). The 
differentiation of the C2 clones is marked by a  large in- 
crease  in  the  expression  of muscle-specific cytoskeletal 
proteins and, in particular, myosin. This is illustrated for 
one clone that was transfected with the wild-type recombi- 
nant  myosin  gene  and  one  clone  transfected  with  the 
G699A mutant myosin gene. The mAb antibody used in 
this screen is directed against an epitope on the NH2 ter- 
minus of the recombinant myosin and does not cross-react 
with the endogenous C2 myosin. 
The clones were classified both on the level of recombi- 
nant myosin expression and on the extent of differentia- 
tion. Strongly positive lines exhibiting good differentiation 
were selected for further analysis. Expression of the re- 
Figure 2.  Expression of recombinant  myosin in C2C12 transfec- 
tants. Stable transfectants were induced to differentiate, and then 
screened by Western blotting for the production of the recombi- 
nant myosin using an mAb (4H7.6) that specifically  recognizes the 
chicken myosin. The analysis of three cell lines is shown: untrans- 
fected C2C12 cells (C2C12), and two clones from transfections 
with the wild-type myosin gene and the G699A mutant myosin 
gene. Clones isolated  with this screen synthesized the recombi- 
nant myosin in differentiated myotubes (mt) but not in myoblasts 
-  (mb). The recombinant myosin was detected in 20--60% of the 
clones that were screened. 
combinant myosin is stable over multiple passages; how- 
ever, the extent and quality of differentiation and the level 
of expression does decrease with extended passage (through 
passage 13). Consequently, all experiments were performed 
with early passages of positive clones. 
Recombinant Myosin Expression 
The presence of the wild-type and G699A mutant trans- 
genes in transfected C2 cell clones was confirmed by PCR 
amplification of genomic DNA.  Oligonucleotide primers 
that  flanked the  position  of the  G699A  point  mutation 
within the myosin coding region were used to amplify the 
target sequences in genomic DNA isolated from untrans- 
fected C2C12  myoblasts, a  cell line transfected with the 
wild-type  myosin  gene  and  a  line  transfected  with  the 
G699A mutant myosin gene (Fig. 3 A). A  1,281-bp frag- 
ment is detected in both clones that had been selected for 
expression of the recombinant myosin gene, and no frag- 
ment is amplified from the C2C12 myoblasts. In designing 
the  site-directed  mutagenesis  primers  to  produce  the 
G699A mutation, an adjacent silent base pair change was 
incorporated to introduce a unique BamHI restriction site 
in the coding region of the myosin cDNA. Consequently, 
when the PCR  products from the wild-type and  mutant 
clones were digested with BamHI, the PCR fragment from 
the mutant was cleaved, producing 736- and 545-bp frag- 
ments, confirming the identification of the mutant cell line. 
The regulation of the recombinant myosin gene expres- 
sion and processing of the transcript were analyzed by RT- 
PCR. A set of primers was designed to analyze splicing on 
the Y-end of the mRNA (Fig. 3 B). The (+) strand primer 
overlapped  the  putative  splice junction  between  exon  1 
and  exon  2  of  the  recombinant  gene.  The  (-)  strand 
primer was selected from within the coding region of the 
myosin cDNA such that if the first intron were properly 
excised from the primary transcript, a  1.5-kbp PCR prod- 
uct would result. Total RNA samples from myoblasts and 
myotubes (6 d after induction) were analyzed by RT-PCR: 
The predicted 1.5-kbp PCR product is detected only in the 
cDNA produced with the myotube RNA samples from the 
cell lines bearing wild-type and mutant myosin genes. This 
indicates  that  the  recombinant  myosin  gene  is  only ex- 
pressed in differentiating myotubes. The size of the frag- 
ment is exactly that predicted, assuming the primary tran- 
script  was  properly  processed,  Similarly,  primers  were 
designed to analyze the processing of the 3'-end of the re- 
combinant gene transcript using a (+) strand probe in the 
chicken cDNA near exon 37 and a (-) strand probe in the 
rat exon 41 (Fig. 3 C). Again the predicted PCR product 
(1.03 kbp) is detected in the cDNA samples from the dif- 
ferentiated myotubes of the clonal lines expressing the re- 
combinant chicken myosin genes. These results indicate 
that the recombinant myosin genes are temporally regu- 
lated and  active only in myotubes and  that  the primary 
transcripts are properly processed. 
The time course of the appearance of the recombinant 
myosin in differentiating myotubes was assayed by SDS- 
PAGE and Western blotting. A clone expressing the wild- 
type myosin was induced to differentiate, and a  high salt 
extract of the cytoskeletal proteins was harvested at inter- 
vals during myotube formation. After transfer to the dif- 
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and RT-PCR analysis of recombinant myosin mRNA. (A)  Ge- 
nomic DNA was isolated from C2C12 cells (lane 1) and cell lines 
expressing wild-type myosin (lanes 2 and 4) and G699A mutant 
myosin (lanes 3 and 5). Primers that flanked the position  of the 
point mutation (G699A) were selected  from the chicken myosin 
cDNA  sequence.  PCR  amplification  using  these  primers pro- 
duces  the  expected 1,281-bp product  with  the  genomic  DNA 
from wild-type and G699A mutant myosin-expressing  cell lines, 
but not C2C12 cells. BamHI restriction  enzyme digestion  of the 
wild-type (lane 4) and G699A mutant (lane 5) PCR products pro- 
duces  735- and 545-bp fragments only with the G699A  mutant 
PCR product.  (B and C) RT-PCR of total RNA isolated  from 
myoblasts (lanes  1, 3, and 5) and myotubes (lanes 2, 4, and 6) 
from C2C12 cells (lanes 1 and 2), a wild-type myosin-expressing 
clone (lanes 3 and 4), and G699A mutant-expressing clone (lanes 
5 and 6). Primers were selected for analyzing the 5'- and the 3'- 
ferentiation  media, the  myoblasts quickly begin to  align 
and fuse, and within 48 h, there is a marked increase in the 
amount of muscle-specific cytoskeletal proteins, most no- 
tably myosin (Fig. 4). However, the recombinant myosin is 
not detected until 4-5 d after induction, at least 48 h after 
the  initial  appearance  of the  muscle-specific C2  myosin 
and well after significant accumulation of the endogenous 
myosin. This suggests that the rat promoter driving expres- 
sion of the recombinant myosin is a late promoter turning 
on  after the  initial  burst  of muscle-specific gene expres- 
sion. The level of expression of the  recombinant myosin 
appeared stable in the myotubes for up to 14 d  (data not 
shown). 
The  stability  of  the  recombinant  myosin  may  be  ac- 
counted for by the observation that this myosin coassem- 
bles with the endogenous C2 myosin into the striated myo- 
fibrils of the myotubes (Fig. 5). The cloned myoblasts were 
grown on collagen-coated glass coverslips, induced to dif- 
ferentiate, and processed for immunofluorescence micros- 
copy 6 d after the appearance of myotubes. The recombi- 
nant  myosin  is  detected,  assembled  into  well-ordered, 
striated myofibrils in these myotubes. Both the wild-type 
myosin (Fig. 5 A) and the G699A mutant myosin (Fig. 5 B) 
coassemble with the C2 myosin, demonstrating that these 
genes produce  assembly-competent proteins.  In addition 
to striated myofibrils, the protein is found diffusely distrib- 
uted  throughout  the  myotubes  along  cytoskeletal  struc- 
tures  and  in  poorly  organized  myosin  filament  bundles, 
sites characteristic of the cytoarchitecture of nascent myo- 
tubes. 
Isolation of the Recombinant Myosin 
Since the recombinant myosin coassembles with the mus- 
cle-specific cytoskeleton, it was readily isolated along with 
the endogenous C2 myosin using typical myosin extraction 
and  fractionation  methods  (Fig.  6).  Myotubes  were  har- 
vested 7-8 d after fusion, lysed, and extracted with Triton 
X-100 to remove soluble proteins and to produce a Triton- 
insoluble cytoskeleton fraction. The myosin was recovered 
from the  cytoskeleton fraction by extraction with  a  high 
salt buffer containing ATP. An acto-myosin superprecipi- 
tate was then formed by overnight dialysis of the high salt 
extract against  a  low salt buffer lacking ATP. The  acto- 
myosin pellet was redissolved in high salt/ATP buffer, and 
the F-actin pelleted to recover an enriched myosin fraction 
that was used in most subsequent assays (Fig. 6 A). The re- 
combinant myosin fractionated with the C2 myosin through- 
out  the  preparation and  amounted to 2-5%  of the  total 
myosin fraction. About 20-40 ~g of recombinant myosin 
was prepared from 0.25-0.5 g of cell pellet. 
As  a  final step,  the  recombinant myosin was partially 
separated from the endogenous C2 myosin by ion-exchange 
end of the mRNA separately.  PCR products of the predicted size 
(1,517 bp for the 5'-end RT-PCR and 1,035 bp for the 3'-end RT- 
PCR) are detected on amplification of the cDNA produced from 
the total RNA. The products are produced only with RNA iso- 
lated from myotubes of cell lines expressing the recombinant myo- 
sin gene. These results indicate that recombinant myosin gene ex- 
pression  is correctly regulated and that primary transcripts  are 
properly spliced. 
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developing myotubes.  Confluent  100-mm  dishes  of myoblasts 
were induced to differentiate by transferring to low serum media. 
A high salt extract of the Triton-insoluble  cytoskeleton was ana- 
lyzed  by SDS-PAGE and Western  blotting.  Myotubes formed 
quickly over the course of several days. The extent of differentia- 
tion is indicated  by the increase in the level of myosin expression, 
which is apparent in the stained  gel. Myosin synthesis increases 
from day 2 to day 7; however, the recombinant myosin is not de- 
tected until 4.5-5 d after induction, suggesting that the rat myosin 
promoter is a late promoter, turning on after the initial induction 
of the muscle-specific gene expression program. 
chromatography  (Fig.  6  B).  The  recombinant  myosin 
elutes in the leading edge of the myosin peak as shown by 
Western  blotting.  The  recombinant  myosin  and  the  C2 
myosin elute with the muscle-specific myosin light chains: 
emb-LC1, LC1, LC2, and a small amount of LC3. This in- 
dicates that the recombinant myosin is a chimeric protein 
containing  mouse muscle-specific light  chains  associated 
with chicken myosin heavy chain sequences. Despite this 
unusual combination, the recombinant myosin has assem- 
bly  and  solubility  properties that  are  comparable to  the 
embryonic mouse myosin. 
Motor Activity of Recombinant Myosin 
Expression of both  the  recombinant myosin and the  en- 
dogenous C2 myosin are induced during myoblast differ- 
entiation.  Therefore,  it  was  necessary  to  devise  an  ap- 
proach that could isolate the recombinant myosin from the 
C2 myosin to selectively assay the motor activity of the re- 
combinant protein. This was accomplished using an anti- 
body  capture  technique  to  prepare  surfaces  for in  vitro 
motility assays (Winkelmann et al., 1995). An anti-S2 mAb 
(10F12.3) that reacts with the chicken myosin but not with 
the C2 myosin was used to selectively tether the recombi- 
nant myosin to antibody-coated glass coverslips. The anti- 
body binds the myosin in the $2 region near the S2-1ight 
meromyosin  junction,  leaving  the  motor  domains  and 
much of the  $2 region free to interact  with  actin and  to 
power the  sliding movement of actin filaments. This is a 
very sensitive method for specifically isolating myosin from 
dilute  mixtures  and  has  been  demonstrated  to  produce 
surfaces that support rapid and uniform sliding movement 
of actin  filaments  at  speeds that  approach the  unloaded 
shortening velocity measured for muscle contraction (Win- 
kelmann et al., 1995). 
The myosin fractions isolated from wild-type and G699A 
mutant myosin-expressing clones, a native myosin isolated 
from adult chicken pectoralis muscle that also reacts with 
the anti-S2 mAb and C2 myosin isolated from an untrans- 
fected  cell line,  were  incubated  with  the  anti-S2-coated 
coverslips. The sliding movement of fluorescently labeled 
actin filaments over these surfaces was recorded by video 
microscopy and  analyzed. The type of movement that  is 
observed is illustrated in Fig. 7, which shows the accumula- 
tion of tracks produced  by single  actin filaments as they 
move over each of these surfaces. Large numbers of indi- 
vidual tracks are apparent, crisscrossing the field over the 
adult  chicken  myosin  (Fig.  7  A)  and  recombinant  wild- 
type  myosin  (Fig.  7  B)  in  the  2-min  time  windows  dis- 
played  here.  Individual  actin  filaments  move  smoothly 
onto  the  myosin-coated surfaces  from the  bulk  solution 
and  often  transit  over distances  of several hundred  mi- 
crons. A  few immobilized actin filaments are also appar- 
ent, as evidenced by the bright spots, but most of the field 
is  dominated  by filament tracks.  The  appearance  of the 
tracks is markedly different for the G699A mutant myosin 
(Fig. 7 C). These tracks were accumulated over 6 min and 
appear much brighter, shorter, and more heavily curved. 
This  is  because  the  actin  filaments  making  these  tracks 
were moving exceptionally slowly over this myosin-coated 
surface. 
In contrast to the directed and active movement as evi- 
denced by the  numerous tracks produced over the  adult 
and recombinant myosin-coated surfaces, the surface incu- 
bated with C2 myosin supports no directed movement and 
produces no long actin movement tracks (Fig. 7 D). The 
actin filaments near the surface gyrated in Brownian mo- 
tion,  producing  a  few short  branched  tracks and  circles; 
however, there was no evidence for binding of filaments to 
the surface or directed movement over the surface in this 
2-min time window or in any of the video recordings. This 
result  confirms  the  selectivity  of  the  antibody  capture 
technique used here. 
Movement of the  actin  filaments was analyzed with  a 
semi-automated tracking program (Bourdieu et al., 1995) 
to determine the  actin filament velocity distributions  for 
adult chicken myosin, wild-type recombinant myosin, and 
G699A mutant myosin (Fig. 8). This analysis first involves 
the delineation of all actin filaments in each video frame, 
followed by frame-to-frame mapping to define the connec- 
tivity in time and to assign a label to each filament. The la- 
beled  filaments  are  then  propagated  through  time,  and 
their shape, time, and position coordinates are stored. The 
track for an individual filament is defined by skeletoniza- 
tion of the superimposed shapes for all frames over which 
the filament has been followed. Hundreds of these tracks 
have been extracted from several minutes of video record- 
ing  for  each  of  the  myosin  surfaces  analyzed.  Several 
tracks are shown for filaments moving over the wild-type 
myosin (Fig. 8 A) and the  G699A mutant myosin (Fig. 8 
B).  The average track duration for the wild-type myosin 
was ~10  s  during  which  the  filaments traveled ~35  mi- 
crons. There is a marked difference in the length and dura- 
tion of the tracks extracted for filaments moving over the 
G699A myosin-coated surfaces. Individual filaments moved 
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Figure 5.  Immunofluorescence analysis of recombinant myosin assembly in stable clones. The recombinant myosins were detected with a 
rhodamine-conjugated  mAb that specifically recognizes the NH2-terminal region of the protein (12C5.3). The recombinant myosins as- 
semble into highly ordered, striated myofibrils in C2 myotubes derived from cloned myoblasts. (A) Immunofluorescence microscopy of 
multinucleated  myotubes formed from a clone expressing the wild-type recombinant myosin. The chicken myosin coassembles with the 
endogenous C2 myosin into striated myofibrils spanning  the entire length of this myotube. (B) Similarly, the G699A mutant myosin is 
found assembled in striated myofibrils. 
very slowly over this myosin, so slowly that they could be 
tracked for as long as 5  min, during which  they traveled 
only a few microns. The limiting factor for tracking these 
filaments was photobleaching. Most of the filaments moved 
persistently over the entire observation period; however, 
the  motion  was  perceptible  only  as  changes  in  filament 
shape or if the video records were fast-forwarded. 
To determine the velocity of movement, the mean arc 
length  coordinates  of the  filament in  each  frame is  pro- 
jected onto the track to produce a time-displacement plot 
with the slope equivalent to the instantaneous velocity of 
the filament moving along the track. Several such time-dis- 
placement plots are shown for filaments moving over wild- 
type myosin (Fig. 8 C) and G699A myosin-coated surfaces 
(Fig.  8  D).  The  predominant  motion  observed over the 
wild-type myosin is smooth gliding movement of the actin 
filaments occasionally interrupted  by short  stalls. This is 
very much like the movement that has been described in 
detail  for  adult  myosin  (Bourdieu  et  al.,  1995;  Winkel- 
mann et al., 1995). The time-displacement curves show pe- 
riods of motion with similar slope (velocity) interrupted by 
very short horizontal segments during which the filaments 
creep  along.  Filaments  moving over the  G699A  mutant 
myosin  produced  time-displacement  curves  that  reveal 
persistent  motion  for hundreds  of seconds  but  covering 
much shorter total distances. 
To compute the mean velocity, the experimental curves 
are broken into a limited number of line segments, and the 
instantaneous velocity for each segment is weighted by the 
duration of the segment and plotted as a probability distri- 
bution. The mean velocity for the wild-type myosin is 3.4 
p.m/s,  somewhat slower than  the  5.5  ixrn/s  measured for 
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(A) Isolation of myosin from C2 myotubes analyzed by SDS-PAGE 
and Western blotting.  Samples  are:  (lane  1)  whole  cell lysate; 
(lane 2) lysis supernatant; (lane 3) high salt/ATP extract of Tri- 
ton-insoluble  cytoskeleton;  (lane 4) high salt-insoluble material; 
(lane 5) supernatant from low salt precipitation;  (lane 6) acto- 
myosin superprecipitate redissolved  in HSB with ATP; (lane  7) 
myosin supernatant after high speed centrifugation to pellet F-actin; 
and (lane 8) F-actin pellet. The recombinant myosin cofraction- 
ates with the endogenous C2 myosin and is readily isolated  as a 
mixture with the C2 myosin. The myosin released with MgATP 
from a superprecipitate with actin (lane 7) was used for most sub- 
sequent experiments,  (B) The myosin sample (lane 7) was puri- 
fied by ion-exchange  chromatography on a Mono Q column  in 
sodium pyrophosphate buffer. The recombinant myosin elutes in 
the leading edge of the myosin protein peak as shown by Western 
blotting (inset). The silver-stained  gel reveals the muscle-specific 
light chains associated with the recombinant myosin. The slower 
migrating  of the two LC1 bands is the embryonic form of this 
light chain. The recombinant myosin has a complete complement 
of muscle-specific light chains. 
the  adult  myosin (Fig.  8  E).  The mean velocity for fila- 
ments moving over the G699A myosin is 0.024 I~m/s (Fig. 
8 F), over two orders of magnitude slower than the wild- 
type myosin. Introduction  of the  G699A  point  mutation 
has a dramatic effect on the motor activity of this myosin. 
Nonetheless,  the  mutant  myosin  supports  sliding  move- 
ment of actin filaments that is persistent, and the tight as- 
sociation of the filaments with the surface suggests that the 
defect is not related to the number of active motors avail- 
able on the surface. 
The motor domain of the  wild-type myosin is derived 
from the chicken gene, which is expressed in early embry- 
onic breast muscle (Molina et al., 1987). The velocity of ac- 
tin filament movement produced by the recombinant wild- 
type myosin (3.4  ___ 0.9 i~m/s)  is similar to that measured 
for  the  embryonic myosin  isolated  either  from  primary 
culture myotubes (3.1  _  1.3 I~m/s) prepared from dll em- 
bryo myoblasts or embryonic breast muscle myosin (3.8 _+ 
0.9 p.m/s) isolated from d15 chick embryos. The embryonic 
myosin samples move actin at ~50-60% of the velocity of 
the adult pectoralis muscle myosin, consistent with previ- 
ous reports (Lowey et al., 1993a). 
Functional Significance of the G699A Mutation 
The dramatic effect of the G699A point mutation on fila- 
ment velocity could result from a large decrease in ATPase 
activity. The actin-activated ATPase activity of the wild- 
type  myosin,  G699A  mutant  myosin,  and  adult  myosin 
were compared in a solid phase assay. The myosin samples 
were  bound  to antibody-coated glass coverslips, and  the 
coverslips were incubated with 10 p~M F-actin at 30°C. The 
phosphate released from Mg-ATP was measured, and the rel- 
ative activity of the  different myosin samples is listed in 
Table I. The wild-type myosin ATPase activity was slightly 
lower  than  that  of  the  control  adult  myosin,  and  the 
G699A  mutant  myosin was  fivefold lower.  The  fivefold 
difference in actin-activated ATPase activity between the 
mutant and either the wild-type or adult myosin is signifi- 
cantly less than expected given the >100-fold difference in 
actin filament velocity in the motility assay. This suggests 
that  the  predominant  effect of G699A  mutation  on  the 
motor activity of myosin is not the rate-limiting transition 
that determines the total cycle time and the maximum rate 
of ATP hydrolysis. 
The surface density of active motors is an important fac- 
tor  in  determining  the  velocity of actin  filament  move- 
ment.  Above a  critical myosin surface  density,  the  actin 
filament velocity saturates at a maximum. That density is 
reached with the antibody capture surfaces using ~4 Ixg/ml 
of the adult myosin (Winkelmann et al., 1995), Below this 
myosin concentration, there is a marked decrease in filament 
velocity until movement stops altogether at very low sur- 
face densities.  The  myosin concentration  dependence  of 
the actin filament velocity was measured for the wild-type 
and G699A mutant myosin (Fig. 9 A). The velocity satu- 
rates at 3.4 I~m/s with the wild-type myosin above 4 }xg/ml, 
and  below this  concentration,  the  velocity begins to de- 
crease similar to the behavior of adult myosin. This con- 
trasts with the G699A mutant myosin that moves the fila- 
ments with a velocity of 0.024 Ixm/s over the entire myosin 
concentration range tested (1-10 ixg/ml). The G699A mu- 
tant myosin can support movement at lower myosin sur- 
face densities than wild-type or adult myosin. This would 
occur if the mutation dramatically slows the rate of release 
of myosin from actin, thereby extending the fraction of the 
total  ATPase cycle spent in  a  strong binding interaction 
with actin. 
Both the maximum velocity of muscle contraction and 
the actin filament velocity in the motility assay are deter- 
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tivity assayed with an in vitro 
motility assay. Glass surfaces 
were coated with an anti-S2 
mAb  (10F12.3)  that  reacts 
with the recombinant myosin 
but not C2 myosin. This sur- 
face was  used  as an  affinity 
support  to  separate  the  re- 
combinant  myosin  from  the 
C2 myosin and to immobilize 
the  myosin  for  the  motility 
assay at 27°C. The motor ac- 
tivity of the recombinant myo- 
sin is illustrated by the accu- 
mulation  of  actin  filament 
tracks  over  a  myosin  satu- 
rated surface. (A) Actin fila- 
ments  tracks  accumulated 
over adult chicken pectoralis 
muscle myosin surface. This 
myosin  was  bound  by  the 
mAb  and  demonstrates  the 
normal  level  of activity ob- 
served with this assay during 
a  2-rain  accumulation  time. 
(B)  The  wild-type recombi- 
nant  myosin supports active 
movement of actin filaments 
similar to  the  adult  myosin 
(2-min  accumulation  time). 
(C)  The  tracks  produced 
over the G699A mutant myosin-coated surface are brighter, much shorter, and curved. This is due to the slow rate of movement of 
these filaments (6-min accumulation time). (D) In contrast, C2 myosin supports no directed movement of actin filaments (2-min accu- 
mulation time). The filaments observed over this surface do not attach but vibrate in Brownian motion and exhibit no directed move- 
ment. 
mined  by the  rate  of dissociation of the  strongly bound 
acto-myosin  complex  at  the  end  of  the  cycle  (Sieman- 
kowski et al., 1985). If this step is significantly slower in the 
G699A mutant, this could explain the greater effect of this 
mutation on the sliding filament velocity than on the actin- 
activated  ATPase  rate.  It  would  also  follow  that  very 
slowly  dissociating  G699A  mutant  crossbridges  would 
interfere  with  faster  cycling  crossbridges  if  both  were 
present in the in vitro motility assay. This prediction was 
tested by preparing surfaces containing a  mixture  of fast 
cycling adult myosin with either the wild-type myosin or 
the G699A mutant myosin (Fig. 9 B). The mixed surfaces 
were prepared by serial dilution of either G699A myosin 
or wild-type myosin with a constant concentration of adult 
myosin  (10  Ixg/ml), and  then  incubation  of the  mixtures 
with antibody capture surfaces. The ratio of adult to wild- 
type or mutant myosin was varied from 0.5:1 through 125:1. 
The  affinity of the  anti-S2 antibody is the  same for both 
the embryonic and adult $2 domains, so the surface den- 
sity of each  motor  is proportional to  this ratio. Further- 
more, at the total myosin concentration used throughout 
the dilution series, the surface density of motors remains 
essentially constant  (600-700  molecules  per  txm2),  such 
that velocity of filament movement would be saturated for 
the adult myosin. 
The wild-type myosin had little effect on the velocity of 
the adult myosin over the entire range tested; this was ex- 
pected given the similarity in ATPase activity and actin fil- 
ament velocity of these  two myosin samples. In contrast, 
the G699A mutant myosin had a dominant negative effect 
on the  filament velocity throughout  the range  tested.  At 
low ratios of adult myosin to  G699A mutant  (0.5:1),  the 
filaments were slowed to 0.09 ixm/s, a 60-fold decrease in 
velocity. Even  at  a  50:1  ratio of adult myosin to  mutant 
myosin, there is still a  50%  inhibition of the filament ve- 
locity. This indicates that a very small number of slowly cy- 
cling G699A mutant crossbridges are sufficient to impose 
a  load on the actin filaments that resists the faster-cycling 
adult crossbridges. The  slow-cycling G699A crossbridges 
are strongly attached for a significantly longer time than the 
fast-cycling crossbridges. Thus,  the predominant effect of 
the G699A mutation is on the dissociation of the strongly 
bound acto-myosin complex at the end of the ATPase cycle. 
Discussion 
A Muscle Myosin Expression System 
We have developed a unique expression system to analyze 
the effect of site-directed mutagenesis on the motor activ- 
ity of a  skeletal muscle myosin. The regulated expression 
plasmid,  pGrMHC,  directs  the  synthesis  of  a  chimeric 
muscle myosin in a  mouse myogenic cell line and permit- 
ted  us  to  manipulate  the  myosin  sequence  and  subse- 
The Journal  of Cell Biology,  Volume 134, 1996  904 60 
E  50 
40 ! 
O 
e'- 
t~  30 
i~  20 
10 
0.20 
0.15 
..Q 
t~  ..Q 
o  O.lO 
0.05 
....  i  ....  i  ,  ,  ,  ,  i  ,  , 
5  10  15 
Time (sec) 
E  Adult 
5.52 + 0.67 p.m/s 
Wild Type 
3.40 + 0.86 p~m/s  /  ? 
1  2  3  4  5  6  7 
Velocity (I.tm/s) 
B 
2'  ~' 
10 Ixm 
D 
4' 
3' 
2, 
0  50  1  oo  150  200  250 
Time (sec) 
F  G699A Mutant 
0.024 + 0.008 ~tm/s 
0  0.01  0.02  0.03  0.04 
Velocity (}xm/s) 
,  i 
0.05 
12 
lO 
O 
3 
4  v 
0.20 
"13  0.15 
0" 
(3"  0.10 =: 
0.05 
Figure  8.  Analysis of motor 
activity  of wild-type myosin 
and  G699A mutant myosin. 
Movement tracks (A and B), 
time-displacement plots  for 
selected  tracks  (C  and  D), 
and velocity probability dis- 
tributions (E and F) are pre- 
sented for wild-type myosin 
(A,  C,  and  E)  and  G699A 
mutant myosin (B, D, and F). 
A  semi-automated  tracking 
program was  used  to  delin- 
eate  actin  filament  tracks. 
The time-displacement plots 
corresponding to the selected 
filaments were  produced by 
projecting  the  mean  arc 
length coordinate of the fila- 
ment onto the track for each 
frame analyzed. Note the dif- 
ference in the time and dis- 
tance scales for the wild-type 
myosin (C)  and G699A mu- 
tant myosin (D).  The dura- 
tion of the  plots for rapidly 
moving filaments is  limited 
by  collisions  between  fila- 
ments.  The  G699A  mutant 
myosin moved so slowly that 
collisions were unlikely, thus 
the  duration  of  movement 
tracks is 10-30 times longer. 
The experimental curves are 
broken into a limited number 
of  line  segments  to  deter- 
mige  the  instantaneous ve- 
locity (slope of the segment). 
A velocity distribution  is pro- 
duced by weighting each instantaneous velocity by the duration of the segment. (E and F) Hundreds of observations are binned and 
plotted as a probability distribution, and the mean velocity is determined by fitting the data to a Gaussian distribution. All motility as- 
says were done at 27°C. 
quently isolate and analyze the recombinant protein. The 
C2C12  cell  line was  selected  because  it  efficiently pro- 
duces the muscle-specific isoform of myosin in relatively 
large amounts and is readily transfected and cloned (Monc- 
man et al., 1993). The development of a regulated expres- 
sion vector was essential because the constitutive expression 
Table I. Actin-activated Myosin ATPase Activity 
nmol/mg  min 
Sample  (n = 4) 
Adult myosin  211 ~ 56 
Wild-type  myosin  188 ± 53 
G699A mutant  myosin  41 ± 6 
Actin alone  0 
Actin-activated  myosin  ATPase activity  measured by incubating  myosin-coated  sur- 
faces with 10 IzM F-actin  in motility  assay buffer  at 30°C. Released inorganic  phos- 
phate from ATP hydrolysis  was quantitated  with malachite  green assay (Kodama et 
al., 1986). Background activity  measured with actin  alone was below the detection 
sensitivity,  as was the Mg-ATPase  activity  of the myosin  surfaces. Activity  data were 
normalized  to the amount  of myosin  bound  on the surfaces, which was quantitated  by 
densitometry of the myosin  heavy chain separated by SDS-PAGE  after eluting  the 
myosin  from  the surface with SDS sample  buffer. 
of the same muscle-specific myosin has been shown to in- 
terfere  with  the  differentiation of C2  myoblasts (Monc- 
man et al., 1993). This suggested that the coordinate ex- 
pression of other myofibrillar components is a prerequisite 
for the proper assembly of myosin and maturation of the 
muscle-specific phenotype. 
The embryonic rat myosin promoter was used as the ba- 
sis for building the expression vector. This promoter has 
been extensively characterized in the C2 myogenic cell line, 
and is temporally regulated and very active (Bouvagnet et 
al., 1987; Moncman, 1993). The design was predicated on 
the desire to include both the 5'  and 3'  untranslated re- 
gions of the rat myosin gene, such that rodent-specific reg- 
ulatory sequences would drive the expression of the em- 
bryonic chicken myosin. The embryonic chicken myosin 
cDNA was used to take advantage of a  library of mAbs, 
and in particular, an anti-S2 antibody (10F12.3) that made 
it possible to selectively isolate and assay the recombinant 
myosin (Winkelmann et al., 1995). The motor domain of 
this myosin is >95% identical to the adult chicken myosin 
motor domain, so comparison to the known structure was 
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Figure 9.  Myosin concentration dependence of the actin filament 
velocity and interaction between motors. (A) The actin filament 
velocity was measured on antibody capture surfaces  incubated 
with various  myosin concentrations.  The dotted line is the con- 
centration  dependence  measured  for  adult  chicken  pectoralis 
muscle myosin (Winkelmann  et al., 1995). The velocity measured 
for the wild type myosin (0) is constant above 4 ixg/ml; however, 
at lower concentrations,  the velocity decreases similar to the be- 
havior of adult myosin. In contrast, the filament velocity powered 
by G699A mutant myosin (A) is constant even below the 2 ixg/ml 
threshold.  (B) Actin filament velocity measured for mixtures of 
adult myosin with varying amounts of recombinant myosin. Sur- 
faces were prepared using the antibody capture technique  with 
mixtures of a constant concentration of adult myosin (10 ixg/ml) 
containing varying amounts of wild-type recombinant myosin (O) 
or G699A mutant myosin (A). The wild-type myosin has little ef- 
fect on the adult myosin over the entire range tested. In contrast, 
the G699A mutant myosin slows the velocities produced by the 
mixture over the entire range.  The velocity  of actin  filaments 
moving over the adult myosin alone was 4.6 ixm/s (O), and over 
the G699A myosin alone, it was 0.024 Ixm/s (A) in these motility 
assays at 27°C. 
another important consideration.  Analysis of the expres- 
sion  of the  recombinant myosin gene indicates  that it is 
properly regulated and the primary transcript is correctly 
processed. The time course of expression suggests that the 
rat promoter is active after the first wave of muscle-spe- 
cific gene expression. The low yield of recombinant myo- 
sin  is  perhaps  related  to  the  late  activation  of the  pro- 
moter. Developmental progression of myosin gene expres- 
sion in C2C12 cells has been reported  (Silberstein  et al., 
1986),  and conditions that favor this progression may be 
useful for increasing the yield of recombinant myosin from 
this expression system. 
The recombinant myosin is functionally very similar to 
the  endogenous  mouse  muscle  myosin.  It  coassembles 
with the mouse myosin light chains that are homologous to 
the  corresponding chicken  fast myosin light  chain.  Both 
the  wild-type and the  mutant  chimeric myosin are inte- 
grated into striated  myofibrils and copurify with the  en- 
dogenous mouse myosin. The phenotypic changes that oc- 
curred when recombinant embryonic chicken myosin was 
expressed constitutively from a viral promoter in C2 cell 
lines are not evident in these cell lines, indicating that ex- 
pression of this myosin does not interfere with early or late 
stages of differentiation  (Moncman et al.,  1993).  Finally, 
the actin-activated ATPase activity and the motor activity 
of the wild-type recombinant myosin are very similar to 
embryonic chicken myosin isolated from breast muscle or 
from primary culture myotubes, samples enriched for the 
chicken gene product. 
There are very few expression systems available for site- 
directed mutagenesis experiments on muscle myosin. Dic- 
tyostelium discoideum has been used extensively and very 
successfully with nonmuscle myosin (Spudich, 1989, 1995), 
and recently, the baculovirus expression system has been 
applied  to  smooth  muscle  myosin  and  cardiac  myosin 
(Sweeney et al., 1994; Trybus, 1994).  However, neither of 
these systems has been very successful with a fast skeletal 
muscle myosin. The level of expression obtained with C2 
cell  line  is comparable to  these  other  systems. Further- 
more, this unique system has the added advantage that the 
myosin  incorporates  into  the  endogenous  cytoarchitec- 
ture, making it possible to analyze features specific to the 
assembly of the muscle-specific isoforms of myosin. 
Rationale for Mutagenesis  of Glycine 699 
Our main goal was to  analyze the  role  of a  highly con- 
served glycine (G699) found in a turn that links the two re- 
active sulfhydryls by replacing it with an alanine to limit 
mobility about this  highly conserved residue. The motor 
activity of the mutant myosin is dramatically affected by 
this point mutation, producing a >100-fold decrease in the 
sliding velocity of actin filaments. The rationale for selec- 
tion of this specific site was based on the myosin structure 
(Fig.  10).  Motion  between  the  reactive sulfhydryls,  SH1 
and  SH2,  has been observed and  analyzed (Wells et al., 
1980; Dalbey et al., 1983).  The separation of these sulfhy- 
dryl groups is influenced by nucleotide binding, and con- 
versely, modification or cross-linking of these sulfhydryls 
can modify ATPase activity and actin binding affinity and 
can trap nucleotide (Reisler et al., 1974; Pemrick and We- 
ber, 1976; Wells and Yount, 1979; Dalbey et al., 1983).  In 
the myosin structure, these residues (C707 and C697) are 
located on well-defined a-helix segments that are joined 
by a turn that produces an 80  ° bend between the two heli- 
ces and places the sulfhydryl groups 18 A  apart (Rayment 
et al., 1993b). In this turn, the conserved glycine (G699) is 
The Journal of Cell Biology, Volume 134,  1996  906 Figure 10.  A  ribbon representation of the structure of myosin $1. The model is oriented to highlight the two short helices that contain 
the reactive sulfhydryls, SH1 and SH2 (shown in light blue). The inset (residues 687-714)  shows the position of the conserved glycine 
(G699) in the turn linking the reactive sulfhydryl helices. The highly conserved helix (475-506) that originates in the cleft and may pro- 
vide a link to the SH1 helix is labeled. The motion of the lever arm is in-and-out of the plane of this diagram. This figure was prepared 
with the molecular graphics program MOLSCRIPT (Kraulis, 1991). 
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of these two helices. 
The short SH1 helix (700-709)  is directly linked to the 
light chain binding domain that acts as a semi-rigid lever 
arm. Motion of the SH1 helix could provide a direct link to 
the lever arm. This small helix also interacts with a longer, 
highly  conserved  helix  (475-506)  that  originates  in  the 
cleft  near  the  ~/-phosphate  site  beneath  the  nucleotide 
pocket. This helix is contiguous with and underlying a ma- 
jor  element  of the  actin  binding  surface  (517-543)  and 
could be sensitive to changes involving cleft opening and 
closure, nucleotide binding, and ",/-phosphate release. Re- 
cently, domain movements that include  the reactive sulf- 
hydryl segment and the highly conserved cleft helix (475- 
506)  have been reported in the structure of myosin head 
fragments  with  bound  nucleotides  (Fisher  et  al.,  1995; 
Smith and Rayment, 1995).  This suggests that these  ele- 
ments play an important role in coupling the actin and nu- 
cleotide binding sites to the lever arm. 
Is G699 a Pivot Point? 
The dramatic change in actin filament velocity caused by 
the G699A mutation suggests that motion about G699 is 
essential for coupling conformational changes in the mo- 
tor domain with movement of the lever arm. The effect of 
the G699A mutation appears restricted to the motor activ- 
ity without  altering the  structural  integrity of the  motor 
domain. The G699A mutant myosin folds normally, binds 
light chains, retains its ability to bind actin and to release 
in the presence of MgATP, and, although it is significantly 
slower,  still  powers  the  sliding  movement  of actin  fila- 
ments. The G699A mutation could have this dramatic ef- 
fect on filament velocity in a number of ways: (a) a large 
decrease in the length of the power stroke (from 10 nm to 
0.1 nm); (b) a dramatic slowing of the rate-limiting transi- 
tion in the ATPase cycle, resulting in a 100-fold increase in 
the total cycle time; (c) a dramatic increase in the duty ra- 
tio (i.e., the time spent in a tightly bound force generating 
state); or (d) some combination of these. 
The mixing experiment shows that even a small number 
of the  slow  G699A  mutant  myosin crossbridges  impede 
faster-cycling crossbridges. This suggests that the predomi- 
nant effect is not a shortening of the power stroke, since, if 
only the length of the power stroke were affected, the mix- 
ture of adult myosin and mutant G699A myosin would be 
expected to move at the velocity of the faster myosin. The 
actin-activated ATPase data indicate that there is a  five- 
fold increase in the total cycle time for the mutant. This 
increase is significant but is not sufficient to explain the 
100-fold decrease in velocity or the dominant effect of the 
mutant  in  the  mixing experiment.  However,  if the  time 
spent tightly bound  to actin is dramatically increased for 
the G699A mutant, then a small number of tightly bound 
crossbridges would  have a  dominant  inhibitory effect on 
the fast-cycling crossbridges as is observed. Furthermore, 
a large change in the duty ratio would also give rise to per- 
sistent motion at the saturated velocity on low density my- 
osin  surfaces,  a  feature  that  also  is  observed  with  the 
G699A mutant myosin. 
Dissociation of ADP at the end of the myosin ATPase 
cycle is necessary for rebinding of ATP to trigger the tran- 
sition  of a  strong to weak binding interaction  of myosin 
with actin. The rate of this step is limiting for the unloaded 
shortening velocity of muscle contraction or sliding move- 
ment  of  actin  filaments  in  vitro  (Siemankowski  et  al., 
1985). We have concluded that this step is inhibited in the 
G699A mutant. A pivoting movement of the lever arm has 
been observed for an ADP-bound state of the acto-myo- 
sin complex (Jontes et al.,  1995;  Whittaker  et al.,  1995). 
Together, these data suggest a model where G699 acts as a 
pivot point for coupling movements in the motor domain 
to lever arm motion. 
This region of the myosin structure  is conserved in all 
members of the myosin gene family. Even in myosin gene 
families that lack the extended c~-helical light chain bind- 
ing domain that forms the lever arm, a carboxyl-terminal 
extension is always found that substitutes for this domain 
(Hammer,  1991;  Wolenski,  1995),  suggesting  that  this 
mechanism may be  common  to  all  myosin  gene  family 
members. 
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